Investigating how MUC1 contributes to therapy resistance in pancreatic cancer
MUC1 in Therapy Resistance
This study is looking at a protein called MUC1 that is found in high amounts in pancreatic cancer to see how it helps cancer cells resist treatments, with the hope that the findings will lead to better ways to fight pancreatic cancer and possibly other types of cancer too.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma Hlth Sciences Ctr NIH-funded |
| Lab location | 1 site (Oklahoma City, United States) |
| Project ID | NIH-10926947 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of MUC1, a protein that is highly expressed in pancreatic cancer, in the resistance of cancer cells to various therapies. By analyzing gene expression profiles and conducting experimental studies, the research aims to uncover how MUC1 affects cancer cell signaling and metabolism, leading to treatment resistance. Patients may benefit from insights gained in this research that could inform more effective treatment strategies for pancreatic cancer and potentially other cancers as well.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pancreatic cancer, particularly those who have experienced resistance to standard therapies.
Not a fit: Patients with cancers that do not express MUC1 or those who are not diagnosed with pancreatic cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that overcome resistance in pancreatic cancer and improve patient outcomes.
How similar studies have performed: Previous research has shown that targeting MUC1 can be effective in overcoming therapy resistance in various cancers, indicating a promising avenue for further exploration.
Where this research is happening
Oklahoma City, United States
- University of Oklahoma Hlth Sciences Ctr — Oklahoma City, United States (Active)
Researchers
- Principal investigator: Hollingsworth, Michael a. — University of Oklahoma Hlth Sciences Ctr
- Study coordinator: Hollingsworth, Michael a.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.